Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 5:07 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2209–2232 of 13,471 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Type 2 Diabetes Mellitus
Interventions: Device: Omnipod M System with study CGM, Standard Therapy plus study CGM; Device
Lead sponsor: Insulet Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 27
States / cities: Los Angeles, California • Newport Beach, California • Santa Barbara, California + 23 more

Conditions: Pituitary Adenoma
Interventions: Not listed
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 100 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: End Stage Kidney Disease
Interventions: CSL300, Placebo; Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 3,110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 166
States / cities: Decatur, Alabama • Huntsville, Alabama • Montgomery, Alabama + 121 more

Conditions: Obesity, Diabetes, Hypertension, Asthma/COPD With Tobacco Dependence
Interventions: CHW Goal Support; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: Not listed
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetes, Insulin Resistance
Interventions: Sitagliptin, Placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Severe Hypoglycemia
Interventions: Proactive Care Management, MyHC-T2D education program; Other · Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Diabetes Mellitus, Type 1
Interventions: Planet T1D; Behavioral
Lead sponsor: 3-C Institute for Social Development; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Pancreas Neoplasms, Pancreatitis, Pancreatic Cyst
Interventions: Not listed
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Phoenix, Arizona • Tucson, Arizona

Conditions: Ovarian Carcinoma
Interventions: docetaxel; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 19 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Familial Ovarian Cancer, Familial Breast Cancer, BRCA1-associate Malignancies, BRCA2-associated Malignancies
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 377 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes Mellitus, Diabetic Retinopathy
Interventions: Melatonin, Placebo; Drug · Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 40 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Type 2 Diabetes Mellitus
Interventions: NPH/Regular 70/30 mix, insulin aspart protamine/insulin aspart 70/30 mix; Drug
Lead sponsor: Dennis G. Karounos, M.D.; Federal
Eligibility: 40 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Stage IV Pancreatic Cancer
Interventions: nab-paclitaxel, Cisplatin, gemcitabine; Drug
Lead sponsor: Pancreatic Cancer Research Team; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 3
States / cities: Scottsdale, Arizona • New Brunswick, New Jersey • Bethlehem, Pennsylvania

Conditions: Pituitary Tumors
Interventions: Technetium Tc 99m EC20; Drug
Lead sponsor: Endocyte; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Prediabetic State, Cardiovascular Diseases, Insulin Resistance, Obesity
Interventions: Low/Mod, High/Mod, High/Vig; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 60 Years to 90 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Adrenal Hyperplasia, Congenital
Interventions: Hydrocortisone sodium acetate; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 3 Years to 18 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
Interventions: Elironrasib, Daraxonrasib; Drug
Lead sponsor: Revolution Medicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 534 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 23
States / cities: Duarte, California • Orange, California • Sacramento, California + 17 more

Conditions: Healthy
Interventions: Canagliflozin, 100 mg, Metformin XR, 500 mg, CANA/MET XR FDC, Formulation 1, 50 mg/1000 mg, CANA/MET XR FDC, Formulation 2, 50 mg/1000 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions: geriatric assessment and telephone call from nurse, geriatric assessment and no call from nurse; Behavioral · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 65 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2025
U.S. locations: 3
States / cities: Commack, New York • New York, New York

Conditions: Advanced Solid Malignancies
Interventions: AZD9574, Temozolomide (TMZ), [11C]AZ1419 3391, Trastuzumab Deruxtecan (T-DXd), Datopotamab Deruxtecan (Dato-DXd); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 695 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 11
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 7 more

Conditions: Hypertension, Dyslipidemias, Type 2 Diabetes, HIV-1-infection
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Charlotte, North Carolina • Durham, North Carolina

Conditions: Pancreas Cancer, Adenocarcinoma of the Pancreas
Interventions: Digoxin, 5Fluorouracil, Calcium Leucovorin, Irinotecan, Oxaliplatin; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Cancer
Interventions: mycophenolate mofetil, placebo; Drug
Lead sponsor: Martin, Paul; Other
Eligibility: 4 Years and older
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 15
States / cities: Duarte, California • Stanford, California • Gainesville, Florida + 11 more

Conditions: Pain
Interventions: Oxymorphone; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes

Proton Radiation Therapy for Pituitary Adenoma

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

Effectiveness of Patient-centered Community Health Worker Support to Help Patients Control Chronic Disease

Dipeptidyl Peptidase-4 Inhibition and Immune Function in HIV

Comparing the Effectiveness of Two Approaches to Preventing Severe Hypoglycemia in Patients With Type 2 Diabetes (PHT2)

Mobile Technology & Online Tools to Track Adherence in Chronic Illness Patients

PROMs After Pancreatectomy

A Phase I Study of Intraperitoneal Hyperthermic Docetaxel

Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer

Sleep, Diabetic Retinopathy and Melatonin

Veterans Inpatient Insulin Study and Transition to Outpatient Therapy

Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA

Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors

Role of Aging and Individual Variation in Exercise Training Responsiveness

Research Study for Children With Salt Wasting Congenital Adrenal Hyperplasia

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants

Geriatric Assessment and Nursing Telephone Intervention in Elderly Women With Ovarian Cancer

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

Addressing Barriers to Achieving Cardiometabolic Disorders Prevention and Treatment Goals for PLWH in the SE US

FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer

Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD)

A Pilot Study of Switching From One Pain Medication to Another (Opioid Rotation)